ARTICLE
Received 2 Apr 2014 | Accepted 29 Oct 2014 | Published 4 Dec 2014
DOI: 10.1038/ncomms6690
Extrachromosomal driver mutations in
glioblastoma and low-grade glioma
Sergey Nikolaev1,*, Federico Santoni1,2,*, Marco Garieri1, Periklis Makrythanasis1,2, Emilie Falconnet1,
Michel Guipponi2, Anne Vannier2, Ivan Radovanovic3,4, Frederique Bena2, Franc¸oise Forestier2, Karl Schaller3,4,
Valerie Dutoit5, Virginie Clement-Schatlo3,4, Pierre-Yves Dietrich5 & Stylianos E. Antonarakis1,2,6
Alteration of the number of copies of double minutes (DMs) with oncogenic EGFR mutations
in response to tyrosine kinase inhibitors is a novel adaptive mechanism of glioblastoma.
Here we provide evidence that such mutations in DMs, called here amplification-linked
extrachromosomal mutations (ALEMs), originate extrachromosomally and could therefore be
completely eliminated from the cancer cells. By exome sequencing of seven glioblastoma
patients we reveal ALEMs in EGFR, PDGFRA and other genes. These mutations together with
DMs are lost by cancer cells in culture. We confirm the extrachromosomal origin of such
mutations by showing that wild-type and mutated DMs may coexist in the same tumour.
Analysis of 4,198 tumours suggests the presence of ALEMs across different tumour types
with the highest prevalence in glioblastomas and low-grade gliomas. The extrachromosomal
nature of ALEMs explains the observed drastic changes in the amounts of mutated
oncogenes (like EGFR or PDGFRA) in glioblastoma in response to environmental changes.
1 Department of Genetic Medicine and Development, University of Geneva Medical School, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. 2 Geneva
University Hospitals—HUG, Service of Genetic Medicine, 4 Rue Gabrielle-Perret-Gentil, 1211 Geneva 4, Switzerland. 3 Department of Clinical Neuroscience,
University of Geneva Medical School, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. 4 Department of Neurosurgery, Geneva University Hospitals—HUG,
4 Rue Gabrielle-Perret-Gentil, 1211 Geneva 4, Switzerland. 5 Center of Oncology, Geneva University Hospitals—HUG, 4 Rue Gabrielle-Perret-Gentil, 1211
Geneva 4, Switzerland. 6 IGE3 institute of Genetics and Genomics of Geneva, 1 rue Michel Servet, 1211 Geneva 4, Switzerland. * These authors contributed
equally to this work. Correspondence and requests for materials should be addressed to S.N. (email: sergey.nikolaev@unige.ch) or to F.S.
(email: federico.santoni@unige.ch) or to S.E.A. (email: stylianos.antonarakis@unige.ch).
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
1
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
H
uman cancers are characterised by the presence of
genomic instability1,2. One form of genomic instability
which makes tumours susceptible to acquiring point
mutations is often referred to as the mutator phenotype3–5. It is
expected that the probability of acquisition of gain-of-function
mutations in oncogenes is considerably lower than the probability
of acquisition of loss-of-function mutations in tumour suppressor
genes, because the first occurs in a few critical sites, whereas the
latter occurs anywhere in the coding sequence of the gene.
Despite that, oncogenes harbour B80% of the driver mutations6.
This could be partially explained by the frequent genomic focal
amplification (FA) of some oncogenes (that is, RTKs like EGFR,
PDGFRA)7,8 which may increase the probability of acquisition of
gain-of-function mutations9–14.
Several sources of evidence suggest that regions of genomic
rearrangements including FAs in cancer may be associated with
high mutation loads. In the germline, the DNA mutation loads
depend on the number of replication cycles15,16, and genomic
rearrangements frequently coexist with the concomitant
mutations17. Notably, the break-induced replication repair
pathway18,19 was recently suggested to be responsible for the
frequent genomic duplications in human cancers20.
Double minutes (DMs) and homogeneously staining regions
(HSR) are the cytogenetic hallmarks of genomic FAs in cancer21.
DMs are extrachromosomal circular DNA molecules without
centromere and are found in the nucleus or cytoplasm enveloped
by a nuclear-like membrane (micronuclei) allowing the
transcription and DNA replication22. The absence of a
centromere in DMs results in a random segregation between
daughter cells through ‘hitchhiking’23. DMs were found in many
tumour types including glioblastomas (GBM)13,24, low-grade
gliomas (LGG), ovary25, breast26, lung27, colon28,29 and
neuroblastoma25,30. The probable mechanism of DM formation
involves non-homologous end joining31–33 which is active in
different tumours, especially in those with defective homologous
recombination34. Therefore the mutation load in DMs is expected
to be higher than that in chromosomal DNA, because the repair
of DNA damage by non-homologous end joining results in
acquisition of point mutations and small indels and the DNA
damage repair mechanism is less efficient in the micronuclei
compared with the nucleus29,35. It is also expected that the
mutational load in the regions amplified as DMs may be
considerably higher than that in the chromosomal nonamplified DNA as this kind of amplification may reach
hundreds of copies per cell or more36.
In this work we describe a novel class of mutations in cancer,
amplification-linked extrachromosomal mutations (ALEMs)
which occur in DMs. ALEMs are detected in GBMs because
they disappear from tumour cells during cell culture. While
ALEMs are most prevalent in GBMs and LGG they also exist in
other tumour types. Based on these findings, we propose a novel
mechanism of acquisition of gain-of-function extrachromosomal
mutations mediated by FAs which may underlie the acquisition of
resistance to therapies.
Results
Amplification-linked mutations. We investigated the genetic
heterogeneity of GBM by exome sequencing of primary tumour
fragments and derived gliomaspheres from seven patients. GBMs
were selected for the study, because these tumours are characterised by frequent FAs in their genomes (450% of the cases)
predominantly in the form of DMs37. We took advantage of the
fact that the cultured GBM spheres in certain conditions can
lose DMs38,39, in order to monitor the fate of point mutations
within FAs.
We observed eight mutations present within FAs in the
primary tumours, and remarkably, all of them were lost in the
gliomaspheres after several passages (Table 1). Neither LOH nor
chromosomal abnormalities have been detected in the corresponding regions in gliomaspheres. Notably, one individual had
four mutations associated with FAs in the primary tumour which
were lost in the spheres (GBM IV-34) (Fig. 1). One of these
mutations, PDGFRA N659K (COSM22415), was within a 5.1 Mb
amplification (chr4:52.86–57.98 Mb), while the other three:
MARS p.G888E, DDIT3 p.P11S and DDIT3 p.S31L were within
an amplification of 1.5 Mb on chromosome 12 (chr12:57.86–
59.31 Mb). The fraction of reads supporting these mutations was
close to 100% in the primary tumour sample (86, 97, 99 and
100%, respectively). In addition we performed fluorescence in situ
hybridization (FISH) analysis of the interphase nuclei of the GBM
IV-34 primary tumour cells and gliomaspheres. The number and
localisations of the PDGFRA signals in the primary GBM cells as
well as their loss in the cell culture strongly suggests that this FA
is present in a form of DMs (Supplementary Fig. 1a,b).
Similar observations were made comparing variants in primary
tumours versus spheres from patients GBM IV-19 and GBM
IV-39. In both tumours, the EGFR (p.A289V and p.S227Y)
mutations and FAs were present in the primary tissues and
gliomaspheres at passage 0; however, they were completely lost at
later passages (Table 1). The DMs amplifications containing the
EGFR locus in the primary tumours and their loss in gliomaspheres in both GBM IV-19 and GBM IV-39 were confirmed by
FISH analyses (Fig. 2, Supplementary Fig. 1c,d).
In addition, we performed metaphase FISH analysis on a GBM
cell line (GBM6 kindly provided by Prof. Paul S. Mischel)
characterised by strong amplification of the EGFR gene. This cell
line is of particular interest as amplified EGFR copies harbour the
in-frame deletion of exons 2–7 coding for the extracellular ligand
(EGFRvIII)9.
FISH was performed with probes targeting EGFR and the
centromere of chromosome 7. EGFR was present in multiple
Table 1 | Mutations lost in the spheres and focal amplifications.
ID
Gene (mut)
GBM IV-34
GBM IV-34
GBM IV-34
GBM IV-34
SK01600*
GBM IV-19
GBM IV-39
DDIT3 (p.P11S)
MARS (p.G888E)
DDIT3 (p.S31L)
PDGFRA (p.N659K)
EGFR (p.C326S)
EGFR (p.A289V)
EGFR (p.S227Y)
Spheres
(% reads)
0
0
0
0
0
57 (0w)
88 (0w)
Tumour
(% reads)
99
97
100
86
36
77
98
Overlap to amplification
in tumour
yes
yes
yes
yes
yes
yes
yes
Amplification in
spheres
No
No
No
No
No
Yes (Now)
Yes (Now)
Passages of
spheres
6
6
6
6
0
0 (3w)
0 (4w)
*The sample was reanalysed from Yost et al.40.
wLater passages have lost the EGFR mutations and amplifications as revealed through Sanger sequencing and FISH.
2
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
7
6
5
4
3
2
1
0
–1
100
200 300 400 500
Exons: FA – 5.12 Mb
3
2
1
0
–2
0
100
200
300
400
500
600
DDIT3
12
8
4
0
–4
600
Coverage ratio (log2)
Spheres
0
Coverage ratio (log2)
MARS
Coverage ratio (log2)
Primary tumour
Coverage ratio (log2)
PDGFRA
0
100
0
100
200
300
400
Exons: FA – 1.45 Mb
500
6
4
2
0
200
300
400
Exons: FA – 0.04 Mb
Exons: FA – 0.27 Mb
Chromosome 4
Chromosome 12
500
Figure 1 | Two examples of Focal Amplifications in primary GBM IV-34 in the tumour tissues which are lost in the gliomaspheres. Y axis- normalised
log2 ratios of the sequence coverages between the tumour and the normal samples. X axis—equidistantly plotted exons. Green line—diploid state in the
tumour. Blue vertical lines depict positions of the mutations. Crosses represent the loss of mutations in gliomaspheres. Red horizontal lines represent
hidden Markov models prediction of the regions of amplifications. Focal Amplifications are estimated taking into account the fraction of tumour cells
in the tumour samples.
extrachromosomal copies 4100. After culturing with erlotinib in
the media, we have repeated the FISH with the same conditions
and, in agreement with our previous observations, all extrachromosomal copies have disappeared. Only the chromosomal
EGFR was detectable.
We have also analysed the data of one patient with GBM
reported in the literature40, where both the primary tumour
tissue and spheres were sequenced. The EGFR p.C326S
(COSM1600351) mutation was within the focally amplified
region and was identified in 36% of reads of the primary
tumour but was lost in the spheres.
Mutations of extrachromosomal origin. These results raise the
question of the origin of the mutations associated with FAs that
are present in the primary GBMs and disappear in neurospheres.
If mutations associated to FAs are of chromosomal origin and
therefore cannot be lost without causing an LOH then their
absence in the spheres could be explained by the expansion of a
different clone without such mutations (Fig. 3a lower panel). On
the other hand if mutations occur after the formation of DMs and
therefore are of extrachromosomal origin, their absence in the
spheres could be explained by the loss of DMs from the tumour
cells (Fig. 3a upper panel). In this case, in one cell wild-type DM
copies must for some time coexist with DM mutated copies.
To validate this hypothesis we reanalysed the DNA sequencing
data from GBM primary tumours from The Cancer Genome
Atlas (TCGA) study10 with FAs and point mutations in EGFR,
focusing on samples where EGFR mutations were present in
o90% of reads (Fig. 3b). The allelic ratio of the germline
heterozygous variants in the tumours was used to estimate the
extent of FAs. Cases with suspicion of more than one FA of the
EGFR locus were excluded (Supplementary Fig. 2). In the seven
remaining TCGA GBM tumours, we detected nine EGFR
mutations showing a level of amplification of more than 36
copies per cell. The allelic ratio in these FAs was close to 1
indicating that almost all sequence reads ( ¼ 495%) originate
Figure 2 | FISH analysis for the detection of EGFR amplification in
GBM IV-19 cells. (a) FISH in primary tumour cells demonstrates euploid
chromosome 7 (green signal) and multiple copies of EGFR scattered all
over the nucleus (red signal). (b) Cultured tumour cells shows euploid
chromosome 7 in green and not amplified EGFR (red signal). Scale
bar ¼ 5 mm.
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
3
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
0
FA
A
A
A
B
Mutation
20
40
60
80
100
3-0750-T1
p.P596R
A
A
A
A
A
B
3-0743-T1
p.A289V
3-0878-T1
p.N280N
3-0878-T1
p.Y275Y
EGFR allele A
EGFR allele B
3-0878-T1
p.A289V
Mutation
A
B
FA
3-0125-T1
p.G598V
A
A
A
A
A
B
3-5139-T1
p.C628F
3-1982-T1
p.G598V
3-0157-T1
p.A289V
Expected if muation is chromosomal
Observed % of reads with EGFR mutation
Allelic percentages in focal amplifications:
germline heterozygous (blue) and somatic (red)
Figure 3 | Somatic mutations in EGFR occur after focal amplifications in GBM. (a) Models of extrachromosomal mutations (in double minutes)
(upper panel) and chromosomal mutation followed by amplification (lower panel). (b) Allelic percentages of heterozygous germline variants and somatic
mutations in EGFR focal amplifications. Heterozygous germline variants of allele A and B (blue and black circles); Somatic mutations (red stars).
GBM tumours were reanalysed from TCGA consortium.
All MUTs; P =0.002; r =0.75
DRIVERs; P =0.055; r =0.66
5.5
Log2 of average copy number of FA
from the amplified copies. In addition, four out of nine somatic
point mutations in EGFR were present in less than 50% of reads,
indicating that a fraction of DM molecules did not contain the
mutation (Fig. 3a upper panel). Therefore, these data confirm the
existence of GBM tumours in which the mutated and wild-type
DM copies coexist and therefore support the scenario, where
the DMs are first formed and the mutation subsequently occurred
in one of the DM copies. Thereafter both populations of DM
molecules coexist until the DMs carrying the mutation are lost or
fixed. We named this new class of mutations as ALEMs.
GBM1
5.0
4.5
GBM1
4.0
LGG1
STAD
BLCA
3.5
3.0
BRCA
LGG1
CESC
UCEC
LUSC
PAAD
STAD
BLCA
LUSC
HNSC
KIRP
HNSC
COAD
UCEC
BRCA COAD
KIRK
OV
2.5
2.0
Prevalence of ALEMs in different tumour types. In order to
investigate the prevalence of co-localisation of FAs and mutations
in various tumour types, we investigated 4,198 tumours from 17
tumour types from the TCGA collection, for which both exome
sequencing and CNV analyses were performed (Supplementary
Table 1).
The FAs matching the characteristics of DMs and HSR31 (more
than four copies and length o6 Mb) were included in the study
as described in the methods. In total we have identified 1,129
somatic mutations across all tumour types which map within
regions of FAs and comprise 0.58% of all studied mutations. We
found a positive correlation between mutation rates and extent of
FAs across all tumour types (P ¼ 0.002, R ¼ 0.75). In each tumour
type the mutation rates within FAs were higher than outside, with
an average increase of 3.67-fold±2.68. The most important
increase of mutation rates within FAs were observed in brain
tumours: LGG(9-fold) and GBM (8-fold) (Fig. 4). These tumour
types are characterised by frequent FAs in the form of DMs. Since
DMs are isolated circular DNA molecules, we hypothesised that a
competition between DM copies bearing different somatic
mutations may result in positive selection for copies with the
strongest oncogenic driver mutation.
To test this hypothesis, we generated a data set of mutations
enriched in oncogenic driver mutations in 54 documented
oncogenes6.
Remarkably 27% of all ‘oncogenic’ driver mutations were
located within FAs. The probability of fixation of ‘oncogenic’
driver mutations in FAs as compared with the total number of
mutations increased in almost all tumour types with the most
pronounced effect in LGG (4-fold ) and GBM (6-fold). A similar
result was obtained in a different data set enriched in putative
driver mutations, where only mutations with at least three
occurrences in the COSMIC v67 database (Supplementary Fig. 3)
were included. Interestingly, when a similar analysis was
4
0
2
4
6
Log2 ratio between mutation rates in FA and outside FA rates
8
Figure 4 | Correlation of increase of mutation rates in FAs with the
FA copy number. Statistical significance was assessed with analysis of
variance. X axis—log2 of the ratio between mutations rates inside FAs and
outside. Y axis—log2 of the average copy number in FAs. Each data point
represents the tumour type. Black—all mutations (N ¼ 14). Orange—
mutations in oncogenes (N ¼ 9). Red line represents equal mutations rates
inside and outside of FAs.
performed with only passenger mutations, many of these were
also localised with FAs in all tumour types, however with a
smaller enrichment compared with what was observed with
putative driver mutations (Supplementary Fig. 3).
Next we investigated which genes exhibit non-random colocalisation of mutations with FAs. When all tumours were
analysed, 212 genes revealed a significant enrichment of
mutations in focally amplified regions (Po0.05). This list of
genes included RTK such as EGFR, PDGFRA, ERBB2 and KIT;
other receptors associated to cancer such as NOTCH3, EPHA6
and other oncogenes including CCNE1, BCL11A, WHSC1L1 and
CDK8 (Supplementary Data 1).
We reasoned that genes mapping near known drivers found in
FAs, may also display increased mutation rate. We observed this
effect in MED1 which is located 0.25 Mb from ERBB2; and in
SHANK2 and PPFIA1 genes near CCND1 (0.84 and 0.65 Mb,
respectively) which is known to be amplified in a form of
DMs27,39,41–45. These closely located genes on the chromosome
are likely to be co-amplified in the same FA (Fig. 5).
To reveal tumour-specific oncogenes that exhibit the pattern of
co-localisation of mutations within FAs, we repeated the gene-bygene analyses independently per each tumour type. The strongest
enrichment of mutations in FAs was observed in EGFR in GBM,
low-grade glioma, head and neck squamous-cell carcinoma, lung
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
and uterine cancer. PDGFRA mutations were enriched in FAs in
GBM, low-grade glioma and lung cancer; and KIT mutations in
lung cancer. Similar co-localisations were observed for NOTCH3
mutations in ovarian and breast cancers; CCNE1 mutations in
uterine cancer; BCL11A mutations in lung cancer and WHSC1L1
mutations in head and neck squamous-cell carcinoma and lung
cancer (Supplementary Fig. 4).
The fraction of putative driver mutations that occurred in FAs
was increased for all tested oncogenes. The most remarkable
effect was observed in EGFR where the percentage of mutations in
FA in all tumours increased from 39% (all mutations) to 65%
(putative driver mutations) followed by PDGFRA (from 17 to
All tumours
EGFR
Focal amplifications (log2)
3.5
3.0
KIT
P-value
7e–04
1e–10
2e–32
PDGFRA
2.5
PEX1
AKAP9
MED1
MLLT3
ERBB2
CCND3
CLOCK
CCNE1
JUP
ITPRIPL1
KRTAP9-1
USP17L2 WHSC1L1
MYOM1
2.0
ZNF536
KRT9
RELN
FES
KRT38
CD22
NLRP4
FBLN2
BCL11A
OSBPL1A
GSX1
REXO1L1
MEP1A
USP34
SGK1
SEC16A
URI1
PPFIA1
TSHZ2
POP4
SHANK2
NOTCH3
CARD11
LOC96610
0.0
0.3
0.1
0.2
Proportion of tumours with mutations in a gene
0.4
Figure 5 | Co-localisations of mutations and amplifications on gene-bygene basis across 17 tumour types and N ¼ 4,198 tumour samples.
X axis—proportion of mutations in Focal Amplifications, Y axis—log2 of the
average copy number in FAs. The area in circle is inversely proportional to
the log2 of the log2 of the P-value (Fisher test). All oncogenes are selected
in red. All oncogenes are presented if they have at least one mutation
in FAs and a P-value less than 0.15, the other genes are presented if they
have at least two mutations in FAs and P-value less than 0.01.
DM generation
50% in LGG) and ERBB2 (from 7 to 11% in all tumours). These
results taken together suggest a positive selection for DM clones
carrying oncogenic driver mutations.
Discussion
In this work we demonstrate the existence of a non-random
association of FAs and likely driver mutations in tumours. In
addition, we propose a mechanism for acquisition of gain-offunction driver mutations in oncogenes mediated by the higher
mutation load observed in DMs.
In several independent cases from this study and from Yost
et al.40, both amplifications and mutations present in the primary
GBM tumours were lost during cell culturing suggesting their
extrachromosomal origin. DM origin of such mutations was
confirmed by revealing the GBM tumours where wild type and
mutated DM copies coexist (Fig. 3a upper panel).
We hypothesise that this phenomenon is taking place in several
steps. The process begins with the generation of the DM
molecules, which may happen in an almost random fashion
across the genome. When the increased number of copies of a
gene provides a proliferative advantage to the tumour cell, this
event has a probability of being expanded in the tumour. The
amplified DNA region is prone to acquisition of an increased
number of variants because of a higher number of DNA copies
(similar mutation rates with corresponding locus of genomic
DNA) or a higher rates of acquisition of variants (higher
mutation rates than in the corresponding locus of genomic DNA)
or a combination of both. Subsequently, DMs with the oncogenic
variants may be subjected to selection based on the random
distribution of DMs among daughter cells. After cell division the
cell with the highest number of DMs harbouring the driver
mutation will have a proliferative advantage. The end point of this
process is the presence of a high number of DMs per cell, where
almost all copies have the driver ALEMs (Fig. 6).
An important consequence of this model is that, in the case of
changes of environmental conditions, the number of DMs could
be modulated and even reduced to zero resulting in the complete
loss of ALEMs. The same mechanism would not be possible if
these amplifications were in a form of HSR. Indeed the selection
and competition between copies of amplified DNA with different
genetic background is only possible between spatially isolated
molecules, such as in the case of DMs. Moreover strong gain-offunction mutations in HSR amplifications would be detectable
only if they have occurred at the early steps of amplification and
were found in a high proportion of copies. Another consequence
Increase of local mutation rate
Activated
oncogenes
Oncogene
DM amplification
ALEM
Increase of ALEMs copies
Competition btw DM molecules
Decrease of ALEMs copies
ALEM Ioss
Cell proliferation
Environmental
changes
Figure 6 | Model of generation and function of ALEMs. After random generation of the DM molecules, the amplified DNA region is prone to
acquisition of an ALEM due to a higher number of DNA copies. The cell with the highest number of DMs harbouring the ALEM will have a
proliferative advantage. In response to environmental stress the cells may accordingly change the amount of DMs (see text for details).
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
5
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
of this model observed in this study is the enrichment of
passenger mutations in FAs which can be explained by the
‘hitchhiking’ effect.
By studying a large number of tumours from publicly available
data (TCGA consortium), we have detected co-localisation of
mutations with amplifications in tumours known to harbour
DMs such as GBM, LGG and LUSC13,24,27. Interestingly, genes
highly affected by ALEMs were members of RTK family, such as
EGFR, PDGFRA and ERBB2. We also noted that driver ALEMs
were 26-fold more frequent in GBM and 13-fold in LGG than the
passenger ALEMs. These two facts confirm the expected positive
selection for the driver mutations in DMs.
Remarkably, our model explains the observations made by
Nathanson et al.9, where the extrachromosomal EGFRvIII
mutation disappeared in response to tyrosine kinase inhibitors.
ALEMs may make tumour cells fast-adaptable to the environmental changes including those induced by anticancer treatments.
For example, we speculate that this mechanism may be utilised to
acquire resistance to vemurafenib treatment in the BRAF V600E
positive tumours46. According to our model amplification of
EGFR which is not a strong oncogenic event per se47–50 may
increase the mutation load and enhance the probability of
acquisition of the driver mutations in EGFR.
In conclusion, we provide evidence to support a novel type of
cancer variants, the ALEMs. They result from a mutagenic
process which is based on the increased mutational load of DMs
that include proliferation-promoting genes such as tyrosinekinases receptors leading to an increased adaptive potential of the
tumour cells.
Methods
Processing of tumours and gliomasphere cultures. In patient samples, tumour
resections were obtained after surgery at the University Hospital of Geneva. After
approval of the ethics committee of the Geneva University Hospitals informed
written consent was obtained for all subjects. Primary tumour samples were cut in
pieces and fresh frozen until analysis. Human biopsies were chopped mechanistically and digested with papain and DNase to generate a cell suspension.
Gliomaspheres were thereof generated as previously described51. Briefly, media
(DMEM-F12, B27 2%) and growth factors (EGF and bFGF at 10 ng ml 1) were
renewed once every 5 days. Peripheral blood was obtained at the time of surgery.
Peripheral blood mononuclear cells were isolated over a Ficoll gradient and frozen
in liquid nitrogen in 10% DMSO until analysis.
DNA extraction and exome sequencing. The overall methodology was as previously described52–54. Briefly, DNA was extracted from the two distant fragments
of frozen tissues, neurosphere cultures (spheres) and peripheral blood lymphocytes
using the QIAamp DNA Mini Kit (Qiagen) for seven patients with GBM. When
little material was available (o0.5 mg), Whole genome amplification was performed
using REPLI-g Mini Kit (Qiagen). Exome capture was conducted using the
SureSelect Human Exon v3 50 Mb (Agilent Technologies) reagents and sequencing
was performed on Illumina HiSeq2000 instrument (Illumina) with paired-end
105 nt reads. Burrows–Wheeler Aligner (BWA) software55 was used to align the
sequence reads to the human reference genome (NCBI build GRCh37/hg19).
SAMtools56 was used to remove polymerase chain reaction (PCR) duplicates and to
call single-nucleotide variants (SNV). Detection of small insertions and deletions
(smINDEL) was conducted with Pindel 0.2.2 software57. The average sequencing
coverage was 155 per DNA sample (Supplementary Table 2). The search for
somatic mutations was restricted to the regions covered at least 20-fold in both the
normal and tumour samples.
Calling of SNVs. The initial list of SNVs was filtered against the common (41%)
germline polymorphisms present in the dbSNP137 and 1,000 genomes databases.
SNVs present in the normal tissue sample from the same patient at a frequency of
41% were also filtered out. In contrast to the SNVs, smINDELs were called with
lower accuracy and, therefore, we report only those smINDELs that were validated
by Sanger sequencing. For both SNVs and smINDELs, we focused on the
mutations that map to the protein coding sequences and to splice sites, as the
untranslated exonic regions were less well covered by the commercially available
exome capture reagents used in this study (Supplementary Data 2).
Calling of LOHs and focal amplifications. Two sources of information from
exome sequencing were used to estimate the somatic copy number alterations:
6
(i) the fractions of reads with the heterozygous germline variants; and (ii) the ratios
of the coverage of the tumour sample and the corresponding normal DNA.
An in-house hidden Markov models based algorithm was used to predict the
regions of FAs taking into account both sources of data. FAs were confirmed
with quantitative PCR (Supplementary Fig. 5). Primers for quantitative PCR are
reported in the Supplementary Table 3.
FISH analysis. Genes amplifications were investigated by FISH analysis using the
LSI EGFR Spectrum Orange/CEP7 Spectrum Green probe (Vysis, Abbott
Laboratories, IL, USA) and the BAC probe RP11-231c18 directed against PDGFRA
(chr4:55,127,335-55,259,498; hg19, spectrum green) and the control probe dj963K6
(4qter, spectrum red).
The FISH signals for each locus-specific FISH probe were assessed under an
Zeiss Axioscop microscope (Zeiss) equipped with specific filters (DAPI/Green/
Red). DAPI II (4,6-diamino-2-phenyindole-2-hydrochloride) was used for
chromatin counterstaining.
TCGA data analysis. The tumours for which exome-sequencing and CNV data
were publicly available in TCGA10 were analysed in this study (Supplementary
Table 1). When several kinds of SNV analyses were available for the same tumours,
we selected those which covered the largest number of samples. We selected
amplifications of more than 4-fold and length less than 6 Mb31.
The Fisher exact test was applied for statistical assessment of non-random
co-localisation of FAs and point mutations.
References
1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell
144, 646–674 (2011).
2. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene
and non-oncogene addiction. Cell 136, 823–837 (2009).
3. Loeb, L. A., Springgate, C. F. & Battula, N. Errors in DNA replication as a basis
of malignant changes. Cancer Res. 34, 2311–2321 (1974).
4. Loeb, L. A., Bielas, J. H. & Beckman, R. A. Cancers exhibit a mutator
phenotype: clinical implications. Cancer Res. 68, 3551–3557, discussion 3557
(2008).
5. Loeb, L. A. Human cancers express mutator phenotypes: origin, consequences
and targeting. Nat. Rev. Cancer 11, 450–457 (2011).
6. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
7. Cancer Genome Atlas, N. Comprehensive molecular characterization of human
colon and rectal cancer. Nature 487, 330–337 (2012).
8. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast
tumours. Nature 490, 61–70 (2012).
9. Nathanson, D. A. et al. Targeted therapy resistance mediated by dynamic
regulation of extrachromosomal mutant EGFR DNA. Science 343, 72–76
(2014).
10. Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155,
462–477 (2013).
11. Sanborn, J. Z. et al. Double minute chromosomes in glioblastoma multiforme
are revealed by precise reconstruction of oncogenic amplicons. Cancer Res. 73,
6036–6045 (2013).
12. Snuderl, M. et al. Mosaic amplification of multiple receptor tyrosine kinase
genes in glioblastoma. Cancer Cell 20, 810–817 (2011).
13. Cancer Genome Atlas, N. Comprehensive genomic characterization defines
human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
14. Ercan, D. et al. Amplification of EGFR T790M causes resistance to an
irreversible EGFR inhibitor. Oncogene 29, 2346–2356 (2010).
15. Kong, A. et al. Rate of de novo mutations and the importance of father’s age to
disease risk. Nature 488, 471–475 (2012).
16. Nikolaev, S. I. et al. Life-history traits drive the evolutionary rates of
mammalian coding and noncoding genomic elements. Proc. Natl Acad. Sci.
USA 104, 20443–20448 (2007).
17. Carvalho, C. M. et al. Replicative mechanisms for CNV formation are error
prone. Nat. Genet. 45, 1319–1326 (2013).
18. Deem, A. et al. Break-induced replication is highly inaccurate. PLoS Biol. 9,
e1000594 (2011).
19. Malkova, A. & Haber, J. E. Mutations arising during repair of chromosome
breaks. Annu. Rev. Genet. 46, 455–473 (2012).
20. Costantino, L. et al. Break-induced replication repair of damaged forks induces
genomic duplications in human cells. Science 343, 88–91 (2013).
21. Storlazzi, C. T. et al. Gene amplification as double minutes or homogeneously
staining regions in solid tumors: origin and structure. Genome Res. 20,
1198–1206 (2010).
22. Shimizu, N. Molecular mechanisms of the origin of micronuclei from
extrachromosomal elements. Mutagenesis 26, 119–123 (2011).
23. Botchan, M. Hitchhiking without covalent integration. Cell 117, 280–281
(2004).
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
ARTICLE
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms6690
24. Canute, G. W. et al. The hydroxyurea-induced loss of double-minute
chromosomes containing amplified epidermal growth factor receptor genes
reduces the tumorigenicity and growth of human glioblastoma multiforme.
Neurosurgery 42, 609–616 (1998).
25. Lundberg, G. et al. Binomial mitotic segregation of MYCN-carrying double
minutes in neuroblastoma illustrates the role of randomness in oncogene
amplification. PLoS One 3, e3099 (2008).
26. Lalic, H., Volavsek, C. & Radosevic-Stasic, B. Chromosomal instability and
double minute chromosomes in a breast cancer patient. Acta Med. Okayama
58, 51–58 (2004).
27. Nielsen, J. L. et al. Evidence of gene amplification in the form of double minute
chromosomes is frequently observed in lung cancer. Cancer Genet. Cytogenet.
65, 120–124 (1993).
28. Von Hoff, D. D. et al. Elimination of extrachromosomally amplified MYC
genes from human tumor cells reduces their tumorigenicity. Proc. Natl Acad.
Sci. USA 89, 8165–8169 (1992).
29. Shimizu, N., Misaka, N. & Utani, K. Nonselective DNA damage induced by a
replication inhibitor results in the selective elimination of extrachromosomal
double minutes from human cancer cells. Genes Chromosomes Cancer 46,
865–874 (2007).
30. Ambros, I. M. et al. Neuroblastoma cells can actively eliminate supernumerary
MYCN gene copies by micronucleus formation—sign of tumour cell
revertance? Eur. J. Cancer 33, 2043–2049 (1997).
31. Vogt, N. et al. Molecular structure of double-minute chromosomes bearing
amplified copies of the epidermal growth factor receptor gene in gliomas. Proc.
Natl Acad. Sci. USA 101, 11368–11373 (2004).
32. Lengauer, C., Kinzler, K. W. & Vogelstein, B. Genetic instabilities in human
cancers. Nature 396, 643–649 (1998).
33. Collis, S. J., DeWeese, T. L., Jeggo, P. A. & Parker, A. R. The life and death of
DNA-PK. Oncogene 24, 949–961 (2005).
34. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast
cancers. Cell 149, 979–993 (2012).
35. Yu, L. et al. Gemcitabine eliminates double minute chromosomes from human
ovarian cancer cells. PLoS One 8, e71988 (2013).
36. Quinn, L. A., Moore, G. E., Morgan, R. T. & Woods, L. K. Cell lines from
human colon carcinoma with unusual cell products, double minutes, and
homogeneously staining regions. Cancer Res. 39, 4914–4924 (1979).
37. Bigner, S. H. & Vogelstein, B. Cytogenetics and molecular genetics of malignant
gliomas and medulloblastoma. Brain Pathol. 1, 12–18 (1990).
38. Schulte, A. et al. Glioblastoma stem-like cell lines with either maintenance or
loss of high-level EGFR amplification, generated via modulation of ligand
concentration. Clin Cancer Res. 18, 1901–1913 (2012).
39. Szerlip, N. J. et al. Intratumoral heterogeneity of receptor tyrosine kinases
EGFR and PDGFRA amplification in glioblastoma defines subpopulations with
distinct growth factor response. Proc. Natl Acad. Sci. USA 109, 3041–3046
(2012).
40. Yost, S. E. et al. High-resolution mutational profiling suggests the genetic
validity of glioblastoma patient-derived pre-clinical models. PLoS One 8,
e56185 (2013).
41. Bigner, S. H., Mark, J. & Bigner, D. D. Cytogenetics of human brain tumors.
Cancer Genet. Cytogenet. 47, 141–154 (1990).
42. Fischer, U. et al. A different view on DNA amplifications indicates frequent,
highly complex, and stable amplicons on 12q13-21 in glioma. Mol. Cancer Res.
6, 576–584 (2008).
43. Phillips, J. J. et al. PDGFRA amplification is common in pediatric and adult
high-grade astrocytomas and identifies a poor prognostic group in IDH1
mutant glioblastoma. Brain Pathol. 23, 565–573 (2013).
44. Del Rey, J. et al. Centrosome clustering and cyclin D1 gene amplification in
double minutes are common events in chromosomal unstable bladder tumors.
BMC Cancer 10, 280 (2010).
45. Gibaud, A. et al. Extrachromosomal amplification mechanisms in a glioma with
amplified sequences from multiple chromosome loci. Hum. Mol. Genet. 19,
1276–1285 (2010).
46. Su, F. et al. Resistance to selective BRAF inhibition can be mediated by modest
upstream pathway activation. Cancer Res. 72, 969–978 (2012).
47. Holland, E. C., Hively, W. P., DePinho, R. A. & Varmus, H. E. A constitutively
active epidermal growth factor receptor cooperates with disruption of G1
cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev.
12, 3675–3685 (1998).
48. Weiss, W. A. et al. Genetic determinants of malignancy in a mouse model for
oligodendroglioma. Cancer Res. 63, 1589–1595 (2003).
49. Wei, Q. et al. High-grade glioma formation results from postnatal pten loss or
mutant epidermal growth factor receptor expression in a transgenic mouse
glioma model. Cancer Res. 66, 7429–7437 (2006).
50. Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling
contributes to insensitivity of BRAF mutant colorectal cancers to RAF
inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012).
51. Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64, 7011–7021 (2004).
52. Nikolaev, S. I. et al. A single-nucleotide substitution mutator phenotype
revealed by exome sequencing of human colon adenomas. Cancer Res. 72,
6279–6289 (2012).
53. Nikolaev, S. I. et al. Exome sequencing identifies putative drivers of progression
of transient myeloproliferative disorder to AMKL in infants with Down
syndrome. Blood 122, 554–561 (2013).
54. Nikolaev, S. I. et al. Frequent cases of RAS-mutated Down syndrome acute
lymphoblastic leukaemia lack JAK2 mutations. Nat. Commun. 5, 4654 (2014).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with BurrowsWheeler transform. Bioinformatics 25, 1754–1760 (2009).
56. Li, H. et al. The Sequence Alignment/Map format and SAMtools.
Bioinformatics 25, 2078–2079 (2009).
57. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern
growth approach to detect break points of large deletions and medium sized
insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
Acknowledgements
This study was supported by grants from the Swiss Cancer League (LSCC 2939-02-2012)
and SER-Swiss Russia to SIN; SLCC2939-02-2012, Novartis14B065, ‘Dinu Lipatti’ to SIN;
ERA-NET to SEA and SIN; SNF 144082, ERC 249968, Foundation ‘ChildCare’ to SEA
and Foundation ‘Damm-Etienne’ to IR; ‘Fondation Artères, Genève’ and ‘Ligue genevoise
contre le cancer’ to PYD. The authors thank Prof. Paul Mischel for kindly providing the
GBM6 cell line and Prof. Thanos Halazonetis for constructive discussion and comments
on the manuscript.
Author contributions
S.I.N., F.A.S., V.C.S., I.R., K.S. and S.E.A. designed the study; S.I.N., F.A.S., M.G. and P.M.
performed statistical analysis; K.S., P.Y.D., V.C.S., I.R. and V.D. collected the samples and
collated clinical data; E.F., A.V., F.B., F.F., V.D. and M.Gu. performed the experiments;
and S.I.N., F.A.S., P.M., S.E.A. analysed the results and wrote the manuscript.
Additional information
Accession codes: Sequence data for exome-sequencing of primary tumour fragments,
matched blood samples and derived gliomaspheres have been deposited in GenBank/
EMBL/DDBJ under the accession code PRJNA263837.
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Nikolaev, S. et al. Extrachromosomal driver mutations in
glioblastoma and low grade glioma. Nat. Commun. 5:5690 doi: 10.1038/ncomms6690
(2014).
NATURE COMMUNICATIONS | 5:5690 | DOI: 10.1038/ncomms6690 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
7